Low‐densitylipoproteincholesterolloweringinreal‐worldpatientstreatedwithevolocumabClinicalCardiologyArticleEarlyRecent,Mar24,./clc.本文由“天纳”临床学术信息人工智能系统自动翻译点击文末“阅读原文”下载本文PDFBackgroundLow‐densitylipoproteincholesterol(LDL‐C)isariskfactorforatheroscleroticcardiovasculardisease(ASCVD).Therearelimitedreal‐worlddataonLDL‐CloweringwithevolocumabinUnitedStatesclinicalpractice.低密度脂蛋白胆固醇（LDL-C）是动脉粥样硬化性心血管疾病（ASCVD）的危险因素。在美国的临床实践中，使用evolocumab降低低密度脂蛋白胆固醇的真实数据有限。HypothesisWeassessedLDL‐Cloweringduring1yearofevolocumabtherapy.我们评估了在1年的evolocumab治疗期间LDL-C的降低情况。MethodsThisretrospectivecohortstudyusedlinkedlaboratory(Prognos)andmedicalclaims(IQVIADx/LRxandPharMetricsPlus?)data.Patientswithafirstfillforevolocumabbetween7/1/and10/31/(indexevent)andLDL‐C?≥?70?mg/dLwereincluded(overallcohort;N=).Additionally,apatientsubgroupwitharecentmyocardialinfarction(MI)within12?months(median?days)beforethefirstevolocumabfillwasidentified(N=).ReductionfrombaselineLDL‐CwascalculatedbasedonthelowestLDL‐Cvaluerecordedduringa12‐monthfollow‐upperiod.这项回顾性队列研究使用了链接实验室（Prognos）和医疗索赔（IQVIADx/LRx和PharMetricsPlus?）数据。包括在年7月1日至年10月31日期间首次服用evolocumab（指数事件）且LDL‐C‐70‐mg/dL的患者（整体队列；N=）。此外，在第一次evolocumab填充前12个月（中位数天）内发现近期心肌梗死（MI）的患者亚组（N=）。根据12个月随访期间记录的最低LDL-C值计算基线LDL-C的降低。ResultsThemean(SD)agewas65(10)years;61.9%ofpatientshadASCVDdiagnosesand70.7%ofpatientswereinreceiptoflipid‐loweringtherapy.Followingevolocumabtreatment,changesinLDL‐Cfrombaselinewere?60%intheoverallcohort(median[interquartilerange(IQR)][–]mg/dLto58[36–84]mg/dL)and?65%intherecentMIsubgroup(median[IQR][–]mg/dLto48[30–78]mg/dL).IntheoverallcohortandrecentMIsubgroup,62.1%and69.7%ofpatientsachievedLDL‐C??70?mg/dL,respectively.平均年龄（SD）为65（10）岁；61.9%的患者诊断为ASCVD，70.7%的患者接受降脂治疗。依沃单抗治疗后，总体队列中LDL-C的变化为?60%（中位数[四分位区间（IQR）][–]mg/dL至58[36–84]mg/dL），近期心肌梗死亚组中LDL-C的变化为?65%（中位数[IQR][–]mg/dL至48[30–78]mg/dL）。在整个队列和近期心肌梗死亚组中，分别有62.1%和69.7%的患者达到了低密度脂蛋白胆固醇（LDL-C）<；70毫克/分升。ConclusionsInthisreal‐worldanalysis,evolocumabwasassociatedwithsignificantreductionsinLDL‐C


转载请注明地址:http://www.pulimaosi.com/plmsjp/8875.html